Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00137696|
Recruitment Status : Completed
First Posted : August 30, 2005
Last Update Posted : December 13, 2005
As poliovirus eradication progresses rapidly, strategies to discontinue oral poliovirus vaccination need to be established. One strategy would be to use inactivated poliovirus vaccine (IPV) transitionally, and this has already occurred in the United States. It is not clear, however, if 3 doses of IPV provide sufficient immunogenicity when administered according to World Health Organization (WHO)/Expanded Programme on Immunization (EPI) schedule in a tropical, developing area where no wild-poliovirus circulates.
Puerto Rico will be the study site for this randomized clinical trial. Healthy infants will be identified at birth in a hospital-system, enrolled within 4 weeks of birth, and randomized into one of two arms: United States of America (U.S.A.) schedule (8, 16, 24 weeks/2, 4, 6 months) or WHO schedule (6, 10, 14 weeks). Both groups will receive IPV at visits 1, 2 and 3. Infants will receive all age-appropriate EPI childhood vaccinations along with IPV, to decrease confusion and inconvenience to the parent. Serum will be collected twice, at visit 1 and visit 4 (30-45 days after IPV-3), to measure antibody titers. Sera will be measured for neutralizing antibodies at the Centers for Disease Control (CDC). Based on the lowest seroconversion rate estimate of 85%, and to have a probability of .80 that the estimate from this study is in error by no more than 10%, the investigators will need to enroll 220 infants in each arm. To compensate for attrition and retain statistical power, the investigators plan to enroll up to 250 infants in each arm. This study is expected to require at least 20 months to complete. Results will provide valuable and timely information applicable to global polio eradication efforts. Any participant found not to be protected after 3 doses of IPV will be given a booster at 9-12 months. Results will provide valuable and timely information applicable to global polio eradication efforts.
|Condition or disease||Intervention/treatment||Phase|
|Poliomyelitis||Biological: Vaccination with inactivated polio vaccine Procedure: Collection of serum||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||500 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Immunogenicity of Inactivated Polio Vaccine in Puerto Rico; A Comparative Cohort Study of Two Vaccination Schedules|
|Study Start Date :||September 2002|
|Study Completion Date :||March 2005|
- Serum will be collected twice, at visit 1 and visit 4 (30-45 days after IPV-3), to measure antibody titers.
- Reports on adverse events will be obtained after each vaccination.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00137696
|Ponce School of Medicine|
|Ponce, Puerto Rico|
|Principal Investigator:||Gustavo H Dayan, MD||Centers for Disease Control and Prevention|
|Study Chair:||Margaret Thorley, MPH||Centers for Disease Control and Prevention|
|Study Chair:||Steve McLaughlin, DV||Centers for Disease Control and Prevention|
|Study Chair:||Mark Pallansch||Centers for Disease Control and Prevention|
|Study Director:||Yasuhiro Yamamura, PhD||Ponce School of Medicine|
|Study Chair:||Nayra Rodriguez||Ponce School of Medicine|